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Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USAThe past ﬁve years have borne witness to remarkable progress in
almost all areas of hepatology, including: improved understand-
ing of the molecular pathophysiology of developmental, infec-
tious, inﬂammatory, metabolic and neoplastic liver diseases;
the introduction of non-invasive diagnostic tools for ﬁbrosis,
and the discovery of direct acting anti-viral agents for hepatitis
C, among many others [1–10]. These advances have resulted in
part from successful efforts to link basic science and clinical
research, as reviewed in a special conference on translational
research organized by the European Association for the Study of
the Liver (EASL) in Lyon, France in November 2013 [11].
While a comprehensive description of progress in the science
and practice of hepatology in these 5 years is beyond the scope of
this commentary, we wish to use this ﬁnal FOCUS piece to high-
light some of the most meaningful advances in our ﬁeld, and to
glimpse into the future of our discipline.Hepatitis C virus infection (HCV)
Basic and clinical research, focused primarily on the development
of potent direct-acting anti-viral agents for HCV, has dominated
the scene of viral hepatitis and promises to yield a profound pub-
lic health beneﬁt. Next-generation sequencing technologies have
made genomic analysis extremely rapid, which is beginning to
change the way liver diseases are discovered and diagnosed.
For example, genome-wide association studies, which explore
the relationship between molecular genotypes and clinical phe-
notypes identiﬁed an allelic polymorphism near the IL28B gene,
predicting a favourable therapeutic response to interferon alpha
and ribavirin in the CC genotype among genotype 1 patients
[12]. Improved understanding of the HCV life cycle led to the gen-
eration of genotype-speciﬁc cell lines that have been used in pre-
clinical studies to select and validate novel targets for HCV. These
have included the NS3-4A protease inhibitors, nucleot(s)ide ana-
logue viral polymerase inhibitors, non-nucleoside inhibitors of
the viral RNA polymerase, NS5A inhibitors, host targeted agents
(HTA), cyclophilin inhibitors and a cellular miRNA antagonist
[13]. Over 30 new direct anti-viral agents (DAA) and HTAs areJournal of Hepatology 20
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Open access under CC BY-NC-ND license.in clinical trials, and have already revolutionized the treatment
of chronic HCV. The swift development of interferon-free proto-
cols using DAA monotherapy or the combined administration of
two or three DAAs or HTAs, administered for 8–12 and up to
24 weeks, is leading to SVR rates between 90% and 100% in geno-
types 10204-6, even in patients with cirrhosis, in those who failed
previous anti-viral therapy, are co-infected with HIV or are re-
infected with HCV post liver transplantation. Two of these agents,
sofosbuvir and simeprevir, have already been licensed in the US
andWestern Europe, and others are expected to be approved dur-
ing the next year.Hepatitis B and D virus infection(s)
There has been remarkable progress in understanding the molec-
ular pathophysiology of persistent HBV infection. This knowledge
has been translated into highly efﬁcient means for prevention
and control of chronic HBV infection, primarily through
vaccination [14]. Yet, complete eradication of overt and occult
HBV infection, through targeting of intra-nuclear circular
covalently closed (ccc) HBV-DNA, remains an elusive goal. A
major breakthrough in this pursuit has been reported by Chinese
investigators who identiﬁed the liver bile acid transporter sodium
taurocholate co-transporting polypeptide (NTCP) as the putative
HBV receptor, expressed on the basolateral membrane of hepato-
cytes [15,16]. The NTCP receptor is thought to account for the
speciﬁc hepatotropism of HBV, which has paved the way for
the development of viral entry inhibitors against HBV and hepa-
titis delta virus (HDV). The ﬁrst example of such an inhibitor,
Myrcludex B, is a synthetic N-acylated pre-S1 derived polypep-
tide, developed in Germany, which efﬁciently inhibits HBV entry
into hepatocytes in culture and in vivo [17–19]. Direct targeting
and silencing of ccc HBV-DNA is only at an early developmental
stage. However, blocking the NTCP receptor and HBV entry into
hepatocytes, in combination with a potent nucleot(s)ide
analogue, are expected to prevent HBV infection of naïve liver
cells.
Efforts have continued to deﬁne and improvenew strategies for
the immunologic control of persistentHBV infection. These include
restoration of defective T-cell functions through inhibition of viral
replication by nucleot(s)ide analogues or blocking of negative
regulatory pathways, development of anti-apoptotic agents,
targeted delivery of cytokines towards infected hepatocytes
through TCR-like antibodies and the development of TLR antago-
nists [20–22].14 vol. 61 j 1196–1198
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Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis (NASH)
The emerging world-wide epidemics of non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are
attracting signiﬁcant attention from basic scientists, epidemiolo-
gists, nutritionists, clinicians, the pharmaceutical industry and
the public alike [8]. While no speciﬁc treatments are available
yet, recent AASLD guidelines recommend weight loss, change in
life-style to incorporate more physical activity, control of hyper-
glycemia and treatment of hyperlipidemia with statins [23].
There has also been meaningful progress in developing more spe-
ciﬁc strategies to control the manifestations of NASH, including
the metabolic syndrome and hyperlipidemia, as well as associ-
ated insulin resistance and diabetes mellitus. At the same time,
clinical trials of speciﬁc agents to treat NASH have begun to show
promise. For example, administration of vitamin E is reportedly
superior to placebo for the treatment of NASH in adults without
diabetes, whereas pioglitazone has no beneﬁt over placebo [24].
At present, there is partial consensus that vitamin E can be rec-
ommended in adults with advanced NASH (albeit not in children
[25]) who do not have diabetes or cirrhosis, although long-term
follow-up data are still lacking. Several agents in preclinical stud-
ies and early clinical trials may offer new tools in the manage-
ment of this clinical challenge. These include pentoxifylline,
obeticholic acid (INT-747), a dual peroxisome proliferator-
activated receptor agonist GFT505, S-adenosylmethionine and
anti-lysyl oxidase monoclonal antibodies, among others [26–28].Hepatic ﬁbrosis
An increasingly comprehensive understanding of the molecular
basis of hepatic ﬁbrosis has emerged from studies, clarifying
the regulation of hepatic stellate cell activation, and the immune
and inﬂammatory responses in liver injury. Characterization of
the reversion of activation in stellate cells during regression of
ﬁbrosis [29,30], the control of stellate cell activation by epige-
netic modulations that are transmissible from parent to offspring
[31], and the roles of adipokines, hormones and cytokines in driv-
ing stellate cell responses [32,33] are among the key ﬁndings that
have begun to shed light on this fascinating cell type. At the same
time, new insights have arisen about the impact of inﬂammatory
cell subsets on ﬁbrosis dynamics [34–36], and the importance of
matrix cross-linking [37].
The effective treatment of HBV and HCV has unveiled the
latent regenerative capacity of the liver, yielding unequivocal evi-
dence that even cirrhosis may be reversible in many patients
with these infections [38,39]. Efforts to validate clinical tests that
non-invasively monitor ﬁbrosis have been spearheaded by the
widespread acceptance of transient elastography as a primary
screening tool for cirrhosis [40], while many newer technologies
to quantify ﬁbrosis non-invasively are actively being developed.Hepatocellular carcinoma
With the rising tide of HCC, worldwide progress is desperately
needed in preventing, detecting and curing this neoplasm, and
our current state of treatment lags far behind that of many other
solid tumours. Nonetheless, the approval of sorafenib as the ﬁrstJournal of Hepatology 2014molecularly targeted therapy for HCC [41] heralded a new era in
managing HCC, but progress after sorafenib’s success has been
slow, with many failed trials of other agents left in its wake.
Meanwhile, efforts continue to identify molecular tissue and cir-
culating biomarkers for HCC. Such marker(s) are intended to
identify subpopulations of patients with chronic liver disease at
increased risk to develop HCC as well as to assess prognosis, pre-
dict recurrence and response to treatment in patients with
already established tumours [42,43]. Yet, while improvement in
the imaging of early HCC has been steady, so far there have been
no new validated circulating biomarkers approved for the detec-
tion of HCC.The future
The American baseball player Yogi Berra euphemistically
remarked, ‘‘It’s tough to make predictions, especially about the
future’’. Nonetheless, we predict a hopeful outlook for a future
that promises an improved prognosis for patients with liver dis-
ease. With effective therapies for controlling or curing HBV and
HCV, we will focus increasingly on public health measures to
reduce the prevalence of advanced liver disease through wide-
spread screening and early treatment, but huge pockets of the
earth’s population will be slow to beneﬁt from these advances,
leading to a continued increase in HCC incidence. However,
appreciation for the marked heterogeneity of HCC foreshadows
an era when treatment of this cancer will be personalized and
more effective. Genetic liver diseases will eventually beneﬁt from
progress in induced pluripotent stem cell technologies that per-
mit correction of single gene defects and liver cell repopulation,
or population of liver support devices with patient-derived cells.
For those with fulminant or alcoholic liver injury, hepato-protec-
tive and regenerative agents may reduce the reliance on liver
transplantation by sustaining liver function through the critical
early period when these illnesses are most life-threatening. Like-
wise, anti-ﬁbrotic therapies are just around the corner, built upon
a solid foundation of progress in basic and translational research
in ﬁbrosis. In contrast, developmental diseases and immune dis-
orders, especially primary sclerosing cholangitis, have seen
almost no progress in the clinical setting, but insights in under-
standing their molecular pathogenesis portend eventual success
in their treatment, albeit not in the immediate future.
With all these exciting prospects, there is little doubt that
hepatology will remain vibrant in the coming years, and the Jour-
nal of Hepatology is certain to have plenty of exciting new
advances on which to focus.Finale
Five years ago the newly appointed Editor of the Journal of Hepa-
tology, Professor Didier Samuel approached us with an ‘‘offer we
could not refuse’’. Speciﬁcally, we were asked to read all accepted
papers for the Journal of Hepatology each month to identify a
report(s) of special interest that merited the readers’ attention,
by writing a commentary for the new FOCUS section in each
issue. Not realizing the magnitude of the task, we agreed enthu-
siastically. Although this enthusiasm has occasionally waned
(most acutely when the monthly deadline approached), we con-
sider ourselves privileged to have gained an early peek at manyvol. 61 j 1196–1198 1197
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exciting developments in hepatology. What we had not antici-
pated is the rich educational experience this task has been, posi-
tioning us at the forefront of a discipline that is enjoying a golden
era of progress. We thank Professor Samuel for his leadership and
the Editorial Board members and readers for their trust in our
perspectives. We are conﬁdent that the Journal of Hepatology will
continue to thrive under the new Editor, Professor Rajiv Jalan and
his leadership team, and we wish them every success.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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